Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class

Bioorg Med Chem Lett. 2020 Sep 1;30(17):127361. doi: 10.1016/j.bmcl.2020.127361. Epub 2020 Jun 20.

Abstract

A novel unsymmetrical structural class of orally bioavailable hepatitis C virus (HCV) nonstructural 5A protein (NS5A) inhibitors has been generated by improving both the solubility and membrane permeability of the lead compound found in our previous work. The representative compound 14, with a 5-hydroxymethylpyrazine group and a 3-t-butylpropargyl group on each side of the molecule, exhibited the best oral bioavailability in this study, inhibiting not only the HCV genotype 1a, 1b, 2a, and 3a replicons with EC50 values in the picomolar range, but also inhibited 1a Q30 mutants induced by launched symmetrical inhibitors with EC50 values in the low nanomolar range.

Keywords: Antiviral; HCV; NS5A; Oral bioavailability; Unsynmmetrical structure.

MeSH terms

  • Administration, Oral
  • Antiviral Agents / chemistry*
  • Antiviral Agents / metabolism
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Genotype
  • Hepacivirus / genetics
  • Hepacivirus / metabolism*
  • Hepatitis C / drug therapy
  • Hepatitis C / pathology
  • Hepatitis C / virology
  • Humans
  • Mutation
  • Pargyline / chemistry
  • Pyrazines / chemistry
  • Structure-Activity Relationship
  • Viral Nonstructural Proteins / antagonists & inhibitors*
  • Viral Nonstructural Proteins / genetics
  • Viral Nonstructural Proteins / metabolism
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Pyrazines
  • Viral Nonstructural Proteins
  • Pargyline
  • NS-5 protein, hepatitis C virus